Sellas Life Sciences Group Inc (NASDAQ: SLS) is a clinical-stage biopharmaceutical company that develops cancer immunotherapy product candidates. The company generates no product revenue as of FY2025, relying instead on equity and warrant financing to fund operations. SLS reported a net loss of $30.9 million for the year ended December 31, 2024, and used $35.4 million in cash for operating activities during that period. For FY2025, the company raised $86.3 million in net cash from financing activities, including $51.0 million from warrant inducement transactions, $23.1 million from a registered direct offering, and $12.6 million from warrant exercises. The company depends on partnerships with pharmaceutical and biotechnology companies as a path to future revenue, alongside successful clinical development and regulatory approval of its product candidates. Operations are conducted with contract research organizations (CROs), contract manufacturing organizations (CMOs), and Memorial Sloan Kettering Cancer Center (MSK) as key external partners.

Revenue model

No product revenue as of the filing period. The company funds operations through equity offerings, warrant exercises, and registered direct offerings. Future revenue is contingent on licensing or partnership agreements with pharmaceutical or biotechnology companies and regulatory approval of product candidates.

Products and services

Cancer immunotherapy product candidates in clinical development. Specific product names are not identified in the provided filing excerpts.

Customers and end markets

No commercial customers as of the filing period. Target end markets are oncology patients and, upon commercialization, healthcare providers and third-party payors including government programs and private insurers.

Value-chain role

Clinical-stage drug developer. Outsources clinical trial operations to CROs, manufacturing to CMOs, and conducts research in collaboration with MSK. Does not manufacture or commercialize products as of the filing period.

Geographic exposure

Primarily U.S.-based operations, with reference to state and foreign regulatory compliance obligations. Specific international revenue or operational footprint not identified in the provided filing excerpts.

Source: SEC 10-K, filed 2026-03-19

Industry: Pharmaceutical Preparations Peers: Ambrx Biopharma Cayman, Inc. Athenex, Inc. Perspective Therapeutics Inc Cidara Therapeutics, Inc. Galera Therapeutics Inc Oncternal Therapeutics, Inc. Scorpius Holdings, Inc. IN8bio Inc Rubius Therapeutics, Inc.